Centre de la Douleur, Pôle Anesthésie Réanimation, CHU Grenoble Alpes, F-38000 Grenoble, France; Grenoble Alpes University, Grenoble Institut Neurosciences, GIN, F-38000 Grenoble, France.
Centre de la Douleur, Pôle Anesthésie Réanimation, CHU Grenoble Alpes, F-38000 Grenoble, France; Grenoble Alpes University, Grenoble Institut Neurosciences, GIN, F-38000 Grenoble, France.
Clin Neurophysiol. 2020 Jul;131(7):1423-1432. doi: 10.1016/j.clinph.2020.03.022. Epub 2020 Apr 10.
To assess the long-term analgesic effects of high-frequency repetitive transcranial magnetic stimulation (rTMS) of the motor cortex in patients with chronic pain syndrome.
The study included 57 patients (orofacial pain, n = 26, pudendal neuralgia, n = 18, and neuropathic limb pain, n = 13) with an "induction phase" of 12 daily rTMS sessions for 3 weeks, followed by a "maintenance phase" of bi-monthly sessions for the next five months.
All pain measures significantly decreased from baseline to the end of the induction phase. Analgesic response, defined as pain intensity decrease ≥ 30% compared to baseline, was observed in 39 patients (68%), who could be differentiated from non-responders from the 7th rTMS session. At the end of the maintenance phase (D180), 27 patients (47%) were still responders. Anxio-depressive symptoms and quality of life also improved. The analgesic response at the end of the induction phase was associated with lower pain score at baseline, and the response at the end of the maintenance phase was associated with lower anxio-depressive score at baseline.
The analgesic efficacy of motor cortex rTMS can be maintained in the long term in various chronic pain conditions. Patients with high pain level and severe anxio-depressive symptoms may have a less favorable profile to respond to the procedure.
The overall impact of rTMS treatment on daily life requires a multidimensional evaluation that goes beyond the analgesic effect that can be achieved.
评估高频重复经颅磁刺激(rTMS)对慢性疼痛综合征患者的长期镇痛效果。
本研究纳入了 57 名患者(口腔面部疼痛,n=26;阴部神经痛,n=18;神经性肢体疼痛,n=13),他们接受了为期 3 周的 12 次每日 rTMS 治疗的“诱导期”,随后进行了为期 5 个月的每两个月一次的“维持期”治疗。
所有疼痛评估指标均从基线显著下降至诱导期结束。39 名患者(68%)出现镇痛反应,即与基线相比疼痛强度下降≥30%,他们可从第 7 次 rTMS 治疗中与无反应者区分开来。在维持期结束时(D180),27 名患者(47%)仍为应答者。焦虑抑郁症状和生活质量也得到改善。诱导期结束时的镇痛反应与基线时的疼痛评分较低相关,而维持期结束时的镇痛反应与基线时的焦虑抑郁评分较低相关。
rTMS 对运动皮层的镇痛效果可以在各种慢性疼痛疾病中得到长期维持。基线时疼痛水平较高且焦虑抑郁症状严重的患者对该治疗的反应可能较差。
rTMS 治疗对日常生活的总体影响需要进行多维评估,不仅仅局限于可实现的镇痛效果。